MX377232B - Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2. - Google Patents

Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.

Info

Publication number
MX377232B
MX377232B MX2017000835A MX2017000835A MX377232B MX 377232 B MX377232 B MX 377232B MX 2017000835 A MX2017000835 A MX 2017000835A MX 2017000835 A MX2017000835 A MX 2017000835A MX 377232 B MX377232 B MX 377232B
Authority
MX
Mexico
Prior art keywords
bcl
treatment
methods
activity
inhibitors
Prior art date
Application number
MX2017000835A
Other languages
English (en)
Inventor
Andrew Souers
Li Chun Wang
Steven Elmore
Stuart J Perper
Tariq Ghayur
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45218888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX377232(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX377232B publication Critical patent/MX377232B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a métodos para tratar lupus sistémico eritematoso, nefritis lúpica o síndrome de Sjögren con compuestos que selectivamente inhiben la actividad de proteínas Bcl-2 anti-apoptóticas. Específicamente, la presente invención está dirigida al tratamiento con compuestos que selectivamente inhiben la actividad de proteínas Bcl-2, con una afinidad menor para inhibir la actividad de otras proteínas de la familia Bcl-2, incluyendo Bcl-xL.
MX2017000835A 2010-11-23 2011-11-22 Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2. MX377232B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41668910P 2010-11-23 2010-11-23
PCT/US2011/061769 WO2012071374A1 (en) 2010-11-23 2011-11-22 Methods of treatment using selective bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
MX377232B true MX377232B (es) 2025-03-04

Family

ID=45218888

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013005849A MX346201B (es) 2010-11-23 2011-11-22 Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.
MX2017000835A MX377232B (es) 2010-11-23 2011-11-22 Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013005849A MX346201B (es) 2010-11-23 2011-11-22 Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.

Country Status (36)

Country Link
US (5) US20120129853A1 (es)
EP (2) EP2642999B1 (es)
JP (2) JP5876067B2 (es)
KR (3) KR20190109590A (es)
CN (2) CN103402521B (es)
AR (1) AR083946A1 (es)
AU (2) AU2011332000B2 (es)
BR (1) BR112013012854B1 (es)
CA (1) CA2820618C (es)
CL (1) CL2013001458A1 (es)
CR (1) CR20130268A (es)
CY (1) CY1118442T1 (es)
DK (1) DK2642999T3 (es)
DO (1) DOP2017000056A (es)
EC (1) ECSP13012710A (es)
ES (2) ES2701603T3 (es)
GT (1) GT201300136A (es)
HR (1) HRP20161762T1 (es)
HU (1) HUE031267T2 (es)
IL (2) IL226490A (es)
LT (1) LT2642999T (es)
MX (2) MX346201B (es)
MY (2) MY165884A (es)
NZ (2) NZ708508A (es)
PH (2) PH12013501006A1 (es)
PL (1) PL2642999T3 (es)
PT (1) PT2642999T (es)
RS (1) RS55545B1 (es)
RU (1) RU2593231C2 (es)
SG (2) SG10201509631SA (es)
SI (1) SI2642999T1 (es)
TW (2) TWI535701B (es)
UA (2) UA113157C2 (es)
UY (1) UY33746A (es)
WO (1) WO2012071374A1 (es)
ZA (1) ZA201303589B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
PT2642999T (pt) 2010-11-23 2017-01-05 Abbvie Ireland Unlimited Co Métodos de tratamento que utilizam inibidores seletivos de bcl-2
US20140335074A1 (en) 2011-12-13 2014-11-13 Buck Institute For Research On Aging Methods for improving medical therapies
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
HK1212240A1 (en) 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
WO2014043223A1 (en) * 2012-09-11 2014-03-20 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
PE20151809A1 (es) 2013-03-13 2015-12-25 Abbvie Inc Procesos para la preparacion de un agente inductor de la apoptosis
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
WO2015171591A1 (en) * 2014-05-05 2015-11-12 Board Of Trustees Of The University Of Arkansas COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
RS62713B1 (sr) 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
PE20181088A1 (es) 2015-08-10 2018-07-09 Dana Farber Cancer Inst Inc Mecanismo de resistencia a inhibidores de bromodominio bet
JP6724136B2 (ja) 2015-11-03 2020-07-15 ジェネンテック， インコーポレイテッド がん治療のためのＢｃｌ−２阻害剤及びＭＥＫ阻害剤の組み合わせ
KR102447884B1 (ko) * 2016-04-21 2022-09-27 바이오벤처스, 엘엘씨 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
JP6651180B2 (ja) * 2016-08-05 2020-02-19 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ Ｂｃｌ−２阻害剤としてのｎ−（フェニルスルホニル）ベンズアミドおよび関連化合物
EP3626241B1 (en) * 2017-06-26 2025-04-23 Shenzhen TargetRx, Inc. Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
US11480568B2 (en) 2017-09-28 2022-10-25 Yeda Research And Development Co. Ltd. Diagnosis of autoimmune diseases
WO2019139902A1 (en) 2018-01-10 2019-07-18 Zeno Royalties & Milestones, LLC Benzamide compounds
CA3088253A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
US20190328729A1 (en) 2018-04-26 2019-10-31 Emory University Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
MX2020009759A (es) 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
AU2019314624B2 (en) 2018-07-31 2022-03-03 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
CA3095699A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
KR102764125B1 (ko) 2018-09-18 2025-02-07 시그널켐 라이프사이언시즈 코포레이션 혈액암 치료를 위한 조합요법
EP3858832A4 (en) 2018-10-29 2022-06-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2 SELECTIVE INHIBITOR
US12319689B2 (en) 2019-05-24 2025-06-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor
CN112707900B (zh) * 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
CN113444078B (zh) * 2020-03-25 2023-07-07 中国科学院上海有机化学研究所 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用
IL297541A (en) 2020-04-24 2022-12-01 Genentech Inc Methods for using anti-cd79b immunoconjugates
EP4129998A4 (en) 2020-04-29 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective bcl-2 inhibitor
JP2023539114A (ja) * 2020-08-21 2023-09-13 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド 全身性エリテマトーデスを治療する組成物及び方法
CA3211639A1 (en) * 2021-03-19 2022-09-22 Volodymyr KYSIL Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors
EP4319800A1 (en) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CN117377672A (zh) 2021-06-04 2024-01-09 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2024102890A2 (en) * 2022-11-11 2024-05-16 The Board Of Regents Of The University Of Texas System Amino acid-benzoic acid oligomers and methods of use thereof for treating cancer

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2128208A (en) 1937-02-27 1938-08-23 Du Pont Alkoxy derivatives of methacrylic acid esters and method of producing them
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DK1019385T3 (da) 1995-09-15 2004-05-24 Upjohn Co Aminoaryloxazolidinon-N-oxider
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
ES2318899T3 (es) 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
WO2000004901A1 (en) * 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
AU776933B2 (en) 1999-12-28 2004-09-23 Eisai R&D Management Co., Ltd. Heterocyclic compounds having sulfonamide groups
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
SK14642003A3 (sk) 2001-06-06 2004-12-01 Eli Lilly And Company Benzoylsulfónamidy a sulfonylbenzamidíny ako protinádorové činidlá
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US20090247613A1 (en) 2002-02-20 2009-10-01 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
ES2286406T3 (es) 2002-02-26 2007-12-01 Astrazeneca Ab Formulacion farmaceutica de iressa que comprende un derivado de celulosa soluble en agua.
CA2477350C (en) 2002-02-26 2013-02-12 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound zd1839
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
PL1768967T3 (pl) 2004-07-20 2009-09-30 Symed Labs Ltd Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne
CN101048140B (zh) 2004-08-27 2013-06-19 拜尔保健公司 用于治疗癌症的药物组合物
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
CA2606147C (en) 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
US20080300267A1 (en) 2005-05-16 2008-12-04 Barun Okram Compounds and Compositions as Protein Kinase Inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP2345412A1 (en) 2005-12-02 2011-07-20 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009039553A1 (en) * 2007-09-27 2009-04-02 The Walter And Eliza Hall Institute Of Medical Research Benzothiazole compounds
US20110123482A1 (en) * 2007-10-01 2011-05-26 The Johns Hopkins University Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide
US9267033B2 (en) 2007-10-01 2016-02-23 Arkema Inc. Blends of biodegradable polymers and acrylic copolymers
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
CN101896068A (zh) * 2007-10-19 2010-11-24 伯恩哈姆医学研究协会 抗凋亡蛋白的萘基抑制剂
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
KR101585848B1 (ko) 2007-11-16 2016-01-15 애브비 인코포레이티드 관절염의 치료 방법
CA2708223A1 (en) 2007-12-06 2009-06-11 Andrew Krivoshik Oral compositions of abt-263 for treating cancer
CN101481363B (zh) * 2008-01-10 2011-05-04 江苏豪森药业股份有限公司 一种制备瑞格列奈的方法
WO2009091912A2 (en) 2008-01-15 2009-07-23 Abbott Laboratories Improved mammalian expression vectors and uses thereof
EP2296664A1 (en) * 2008-04-15 2011-03-23 Burnham Institute for Medical Research An inhibitor of anti-apoptotic proteins
MY160340A (en) 2008-10-07 2017-02-28 Astrazeneca Uk Ltd Pharmaceutical formulation 514
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP3666758A1 (en) * 2008-12-05 2020-06-17 AbbVie Inc. Process for the preparation of a sulfonamide derivative
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
MX2011007681A (es) 2009-01-19 2011-08-08 Abbott Lab Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
CN104945311A (zh) 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
RU2535347C3 (ru) * 2009-05-26 2019-05-14 ЭббВи Айэленд Анлимитед Компани Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
PT2642999T (pt) * 2010-11-23 2017-01-05 Abbvie Ireland Unlimited Co Métodos de tratamento que utilizam inibidores seletivos de bcl-2
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent

Also Published As

Publication number Publication date
US20160235760A1 (en) 2016-08-18
US20180369250A1 (en) 2018-12-27
RS55545B1 (sr) 2017-05-31
HUE031267T2 (en) 2017-06-28
US9345702B2 (en) 2016-05-24
CN105664164B (zh) 2020-05-05
CN103402521B (zh) 2016-01-20
KR20180030257A (ko) 2018-03-21
CN103402521A (zh) 2013-11-20
ES2701603T3 (es) 2019-02-25
AU2016204396B2 (en) 2017-10-26
US20150150870A1 (en) 2015-06-04
HRP20161762T1 (hr) 2017-02-24
LT2642999T (lt) 2017-01-25
MY191300A (en) 2022-06-14
MX2013005849A (es) 2013-07-05
ECSP13012710A (es) 2013-08-30
PH12016500939A1 (en) 2017-06-14
UA113157C2 (xx) 2016-12-26
EP3028702A1 (en) 2016-06-08
CN105664164A (zh) 2016-06-15
UY33746A (es) 2012-06-29
ZA201303589B (en) 2014-07-30
DK2642999T3 (en) 2017-01-09
NZ708508A (en) 2016-06-24
CR20130268A (es) 2013-10-17
PH12016500939B1 (en) 2018-11-09
US9872861B2 (en) 2018-01-23
US20200222413A1 (en) 2020-07-16
MY165884A (en) 2018-05-18
AU2016204396A1 (en) 2016-07-14
CA2820618C (en) 2020-04-21
IL251845B (en) 2019-06-30
AR083946A1 (es) 2013-04-10
SI2642999T1 (sl) 2017-01-31
JP5876067B2 (ja) 2016-03-02
TW201302705A (zh) 2013-01-16
AU2011332000B2 (en) 2016-07-07
GT201300136A (es) 2014-08-05
JP2013543896A (ja) 2013-12-09
RU2593231C2 (ru) 2016-08-10
US20120129853A1 (en) 2012-05-24
EP2642999A1 (en) 2013-10-02
JP2016117744A (ja) 2016-06-30
TWI620736B (zh) 2018-04-11
ES2603129T3 (es) 2017-02-23
EP3028702B1 (en) 2018-09-12
TWI535701B (zh) 2016-06-01
EP2642999B1 (en) 2016-09-28
CL2013001458A1 (es) 2013-10-04
IL226490A0 (en) 2013-07-31
BR112013012854A8 (pt) 2018-01-16
NZ610746A (en) 2015-06-26
BR112013012854A2 (pt) 2016-08-23
UA119150C2 (uk) 2019-05-10
TW201630885A (zh) 2016-09-01
SG190399A1 (en) 2013-06-28
WO2012071374A1 (en) 2012-05-31
KR101841084B1 (ko) 2018-03-23
IL226490A (en) 2017-05-29
AU2011332000A1 (en) 2013-06-06
BR112013012854B1 (pt) 2019-08-06
PH12013501006A1 (en) 2022-03-30
RU2013128544A (ru) 2014-12-27
DOP2017000056A (es) 2017-03-31
CY1118442T1 (el) 2017-06-28
PT2642999T (pt) 2017-01-05
SG10201509631SA (en) 2015-12-30
KR20190109590A (ko) 2019-09-25
PL2642999T3 (pl) 2017-04-28
KR20140004659A (ko) 2014-01-13
CA2820618A1 (en) 2012-05-31
IL251845A0 (en) 2017-06-29
JP6215368B2 (ja) 2017-10-18
US20170232000A9 (en) 2017-08-17
MX346201B (es) 2017-03-09

Similar Documents

Publication Publication Date Title
MX377232B (es) Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.
PH12018501827A1 (en) Cancer treatment
EA201290837A1 (ru) Лечение волчаночного нефрита с применением лаквинимода
MD4635C1 (ro) Compuşi de chinolină substituiţi selectiv
MX363708B (es) Compuestos de quinolina selectivamente sustituidos.
MY172926A (en) Tetrahydropyrazolopyrimidine compounds
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2009010057A (es) Compuesto de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de beta-secretasa.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
WO2012065102A3 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
CA2895138C (en) Herbicidal agents containing aclonifen
EA201491876A1 (ru) Азотсодержащее бициклическое ароматическое гетероциклическое соединение
BR112013003740A2 (pt) composições algicidas sinergísticas incluindo derivados de hidrazona e cobre
BR112013003994A2 (pt) composições fungicidas e algicidas sinergísticas incluindo 7-hidróxi-indanona benzoil hidrazonas e cobre
WO2008008841A3 (en) Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders
AU2011262991A1 (en) Gemini virus replication inhibitor
WO2010046461A3 (en) Treatment of intracellular bacterial infections
CL2012003091A1 (es) Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.
WO2011097027A3 (en) Methods for treating or inhibiting infection by clostridium difficile
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
UA42812U (ru) Использование мази тиотриазолина в качестве агента, обладающего фотопротекторными свойствами